Theralase Technologies Inc. (CVE:TLT – Get Free Report) fell 10.6% during mid-day trading on Wednesday . The stock traded as low as C$0.21 and last traded at C$0.21. 122,607 shares traded hands during trading, an increase of 2% from the average session volume of 119,964 shares. The stock had previously closed at C$0.24.
Theralase Technologies Stock Down 6.4 %
The company has a debt-to-equity ratio of 14.85, a quick ratio of 3.40 and a current ratio of 1.91. The firm has a market capitalization of C$53.57 million, a price-to-earnings ratio of -11.72 and a beta of 1.36. The firm has a fifty day moving average price of C$0.27 and a 200 day moving average price of C$0.24.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- Following Congress Stock Trades
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Why Energy Transfer Belongs on Your Watchlist
- How to Capture the Benefits of Dividend Increases
- Why Wayfair Stock May Be a Hidden Gem for Value Investors
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
